Literature DB >> 16966683

Reaching first base in the treatment of metastatic melanoma.

Alexander M M Eggermont.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966683     DOI: 10.1200/JCO.2006.07.3593

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites.

Authors:  Amod A Sarnaik; Jonathan S Zager; Vernon K Sondak
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

Review 2.  The cancer cell's "power plants" as promising therapeutic targets: an overview.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-02       Impact factor: 3.853

3.  The cost of unresectable stage III or stage IV melanoma in Italy.

Authors:  Michele Maio; Paolo Ascierto; Alessandro Testori; Ruggero Ridolfi; Emilio Bajetta; Paola Queirolo; Michele Guida; Antonella Romanini; Vanna Chiarion-Sileni; Jacopo Pigozzo; Anna Maria Di Giacomo; Mario Calandriello; Guido Didoni; Marck van Baardewijk; Cyril Konto; Carlo Lucioni
Journal:  J Exp Clin Cancer Res       Date:  2012-11-01

4.  Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.

Authors:  Einar Birkeland; Christian Busch; Elisabet Ognedal Berge; Jürgen Geisler; Göran Jönsson; Johan Richard Lillehaug; Stian Knappskog; Per Eystein Lønning
Journal:  Clin Exp Metastasis       Date:  2013-05-15       Impact factor: 5.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.